FDA approves gene therapy for treatment of high-risk bladder cancer
The FDA approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating adenoviral vector-based gene therapy for the treatment of high-risk bladder cancer.
The FDA approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating adenoviral vector-based gene therapy for the treatment of high-risk bladder cancer.
Scientists in the US used a mechanism that zebrafish rely on to repair their damaged hearts and then combined it with viral vectors.